An Ann Arbor-based cancer sequencing and testing company sees opportunity to grow into an area of market superiority via a new partnership with one of the world's largest pharmaceutical companies.
Strata Oncology Inc., which bills itself as a "precision oncology company," announced Tuesday…
Strata Oncology Announces the Strata PATH Trial with Pfizer as First Pharma Partner
The new platform clinical trial will evaluate FDA-approved therapies in novel biomarker profiles learned from real-world data
News provided by
Share this article
Share this article
ANN ARBOR, Mich., Mar. 2, 2021 /PRNewswire/ Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced the Strata
Precision Indications for
Approved
Therapies, or Strata PATH, trial. Strata PATH is a multi-drug, multi-arm, biomarker-driven clinical trial designed to evaluate the efficacy of FDA-approved targeted- and immunotherapies in new Strata-defined biomarker indications. Pfizer Inc. (NYSE: PFE) will provide marketed, targeted drugs for four study arms at no cost to participants. Additional pharmaceutical companies are expected to participate after the study launch.
Strata Oncology Announces the Strata PATH Trial with Pfizer as First Pharma Partner investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Strata Oncology Announces Personalized Recurrence Monitoring Trial
Study to Evaluate Strata s Ability to Detect Tumor Recurrence using Liquid Biopsy and Monitor Treatment Effectiveness for Patients with Early-Stage Solid Tumors
News provided by
Share this article
Share this article
ANN ARBOR, Mich., Jan. 13, 2021 /PRNewswire/ Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced plans to begin enrolling the Sentinel Trial in the first half of 2021. Sentinel is a prospective, observational study designed to enroll approximately 100,000 patients diagnosed with stage 1-3 solid tumors and indicated for surgery or definitive therapy. The study will evaluate the ability of Strata s investigational liquid biopsy assay to detect disease recurrence and to monitor treatment effectiveness in patients across solid tumors.
Share this article
Share this article
ANN ARBOR, Mich., Jan. 8, 2021 /PRNewswire/ Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced that Dan Rhodes, Ph.D., co-founder and Chief Executive Officer of Strata Oncology will present at the upcoming virtual J.P. Morgan 39
th Annual Healthcare Conference on January 13, 2021, at 8:05 a.m. Eastern Time.
About Strata Oncology
Strata Oncology, Inc. is a precision medicine company dedicated to delivering the best possible treatment for each patient with cancer. The company combines molecular profiling, real-world data, and a large-scale clinical trial platform to identify and deliver optimal treatments for patients with cancer. StrataNGS is a comprehensive genomic profiling test that features the lowest tumor tissue requirements in the industry so that more patients can get the results and treatments they need. For more information visit www.strataoncology.com.